Evaluating a Clinician Support Algorithm to Enhance Implementation of Evidence-Based Chemotherapy-Induced Peripheral Neuropathy Assessment and Management Recommendations
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 226
- Locations
- 1
- Primary Endpoint
- Clinician Medical Record Abstraction Form
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.
Detailed Description
This research study will test a new clinician decision support tool for the assessment and management of CIPN. The algorithm is designed to help clinicians make decisions about which strategies to use for the assessment and/or management of CIPN. The investigators need to recruit participants receiving chemotherapy that is known to cause CIPN to determine how well the algorithm works to increase clinicians' use of recommended CIPN assessment and management strategies.
Investigators
Robert Knoerl, PhD, RN
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Clinician Medical Record Abstraction Form
Time Frame: From enrollment until the date of the patient's visit 3 time point, assessed up to approximately 10 weeks.
Frequency of clinician CIPN assessment and management documentation for each period.
Secondary Outcomes
- Feasibility of Algorithm Implementation(From enrollment to until all patient participants complete both study periods, assessed up to approximately one year.)
- European Organization of Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20): Sensory and Motor Subscales(From enrollment until the date of the patient's visit 3 time point, assessed up to approximately 10 weeks.)
- Patient-Reported Outcomes National Cancer Institute Common Terminology Criteria for Adverse Events CIPN Severity and Interference Items(From enrollment until the date of the patient's visit 3 time point, assessed up to approximately 10 weeks.)
- 0 - 10 Worst CIPN Numerical Rating Scale(From enrollment until the date of the patient's visit 3 time point, assessed up to approximately 10 weeks.)
- Adapted Acceptability E - Scale(From enrollment to until all patient participants complete both study periods, assessed up to approximately one year.)